ecancermedicalscience

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

28 Feb 2017
Herman Andrés Perroud, O Graciela Scharovsky, Viviana Rosa Rozados, Carlos María Alasino

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Related Articles

Clara Pierini, Clara Mariano y Jelicich, Fabiola Bascuñán Acuña, María De San Martín, Aldana Casati, Cecilia Casullo, Marta Díaz Madero, Delfina Grennon Viel, Estefania Marzik, Gabriela Rodriguez, Victoria Viel Temperley
Ochomo Edwin Onyango, Philiph Tonui, Peter Itsura, Elkanah Omenge Orang'o, Kapten Muthoka, Sayo Loice, Benard Ochieng Samba, Barry Rosen, Patrick Loehrer, Susan Cu-Uvin
Abeir El-Mogassabi, Heithum Saleh Baiu, Nadin Omer Hassan, Enas Mohamed Salem, Lugien Elshakmak, Khalil A K Tamoos, Mohammed Zidan, Asma Rajab Ben Rashid, Ala Elhoudiri, Sama Elmehdawi, Dania Shareia